Clinical Trials Logo

Clinical Trial Summary

Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication of critical illness. Retrospective data suggest that early application of IgM-enriched intravenous immunoglobulin (IVIG) may prevent or mitigate CIPNM. Therefore, the primary objective was to assess the effect of early IgM-enriched IVIG versus placebo to mitigate CIPNM in a prospective setting.


Clinical Trial Description

Background: Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication of critical illness. Retrospective data suggest that early application of IgM-enriched intravenous immunoglobulin (IVIG) may prevent or mitigate CIPNM. Therefore, the primary objective will be to assess the effect of early IgM-enriched IVIG versus placebo to mitigate CIPNM in a prospective setting.

Design: Prospective, randomized, double-blinded and placebo-controlled trial

Setting: Eight-bed medical ICU of a university hospital.

Participants: Critically ill patients will be screened for eligibility defined as multiple organ failure (MOF) and SIRS/sepsis. Patients fulfilling these criteria will be further assessed by a neurologist for clinical signs of CIPNM.

Critically ill patients with multiple organ failure (MOF), SIRS/sepsis, and early clinical signs of CIPNM will be randomized. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01867645
Study type Interventional
Source Medical University of Vienna
Contact
Status Terminated
Phase Phase 1
Start date December 2004
Completion date April 2011

See also
  Status Clinical Trial Phase
Recruiting NCT06040567 - Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
Enrolling by invitation NCT04461613 - Physical Activity in Persons With Charcot-Marie-Tooth: Developing a Measurement Instrument N/A
Enrolling by invitation NCT06359561 - Assessment of Effectiveness and Stimulation Coverage of Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy in Patients With Cervical Lead Placement
Recruiting NCT06044662 - Prognostic Value of Biomarkers in Polyneuropathy.
Completed NCT00050245 - Rituximab to Treat Neuropathy With Anti-MAG Antibodies Phase 2
Not yet recruiting NCT01718015 - Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy N/A
Completed NCT03765489 - Electrical Muscle Stimulation in the Development of Acquired Weakness in Patients With Severe Sepsis and Septic Shock N/A
Completed NCT01370837 - Neurogenic Inflammation in Diabetes N/A
Not yet recruiting NCT02061059 - Cost-effectiveness of In-shoe Pressure Measurement for Therapeutic Shoes N/A
Recruiting NCT06377033 - Using the EHR to Advance Genomic Medicine Across a Diverse Health System N/A
Not yet recruiting NCT06390527 - Ultrasonography in Diagnosis of Polyneuropathy
Recruiting NCT05188690 - Polyneuropathy and COVID-19
Completed NCT00231673 - A Study To Evaluate The Effect Of Topiramate On Clinical And Electrophysiological Parameters In Subjects With Diabetic Peripheral Polyneuropathy Phase 2
Recruiting NCT03237494 - TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
Active, not recruiting NCT03617185 - Effect of Exercise and Surgical Weight Loss on Polyneuropathy N/A
Active, not recruiting NCT02753036 - Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer
Completed NCT01263132 - Neuropathic Pain Management Phase 3
Completed NCT00162968 - Escitalopram as a Treatment for Pain in Polyneuropathy Phase 4
Completed NCT04664426 - Sensory Neuropathy Scores Validated by Quantitative Sensory Testing and Nerve Conduction Studies for Kidney Transplant Recipients
Recruiting NCT05023889 - Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy Early Phase 1